Walleye Trading’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $151K | Sell |
800
-4,400
| -85% | -$769K | ﹤0.01% | 3263 |
|
|
2025
Q4 | $884K | Buy |
+5,200
| New | +$797K | ﹤0.01% | 2457 |
|
|
2024
Q3 | – | Sell |
-10,500
| Closed | -$1.12M | – | 4341 |
|
|
2024
Q2 | $1.12M | Buy |
10,500
+4,900
| +88% | +$539K | ﹤0.01% | 1987 |
|
|
2024
Q1 | $674K | Sell |
5,600
-7,600
| -58% | -$931K | ﹤0.01% | 2570 |
|
|
2023
Q4 | $1.62M | Sell |
13,200
-12,800
| -49% | -$1.6M | ﹤0.01% | 2086 |
|
|
2023
Q3 | $3.37M | Buy |
26,000
+20,600
| +381% | +$2.74M | 0.01% | 1391 |
|
|
2023
Q2 | $669K | Buy |
5,400
+2,800
| +108% | +$377K | ﹤0.01% | 2515 |
|
|
2023
Q1 | $380K | Sell |
2,600
-300
| -10% | -$44.4K | ﹤0.01% | 3012 |
|
|
2022
Q4 | $462K | Sell |
2,900
-21,300
| -88% | -$3.12M | ﹤0.01% | 2872 |
|
|
2022
Q3 | $3.23M | Buy |
24,200
+23,600
| +3,933% | +$3.59M | 0.01% | 1336 |
|
|
2022
Q2 | $94K | Sell |
600
-1,248
| -68% | -$192K | ﹤0.01% | 4135 |
|
|
2022
Q1 | $288K | Sell |
1,848
-6,600
| -78% | -$958K | ﹤0.01% | 3473 |
|
|
2021
Q4 | $1.08M | Buy |
8,448
+100
| +1% | +$13.1K | ﹤0.01% | 2180 |
|
|
2021
Q3 | $1.09M | Sell |
8,348
-4,292
| -34% | -$648K | ﹤0.01% | 2114 |
|
|
2021
Q2 | $2.25M | Sell |
12,640
-22,160
| -64% | -$3.84M | 0.01% | 1413 |
|
|
2021
Q1 | $5.72M | Buy |
34,800
+34,000
| +4,250% | +$5.59M | 0.03% | 572 |
|
|
2020
Q4 | $132K | Sell |
800
-7,700
| -91% | -$1.15M | ﹤0.01% | 3780 |
|
|
2020
Q3 | $1.21M | Sell |
8,500
-5,100
| -38% | -$632K | 0.01% | 1507 |
|
|
2020
Q2 | $1.5M | Sell |
13,600
-17,200
| -56% | -$1.9M | 0.01% | 1337 |
|
|
2020
Q1 | $3.07M | Sell |
30,800
-7,900
| -20% | -$1.02M | 0.02% | 597 |
|
|
2019
Q4 | $5.78M | Buy |
38,700
+3,000
| +8% | +$408K | 0.04% | 503 |
|
|
2019
Q3 | $4.58M | Buy |
35,700
+8,200
| +30% | +$1.1M | 0.04% | 510 |
|
|
2019
Q2 | $3.92M | Buy |
27,500
+7,500
| +38% | +$1.01M | 0.03% | 602 |
|
|
2019
Q1 | $2.86M | Buy |
20,000
+5,400
| +37% | +$704K | 0.02% | 815 |
|
|
2018
Q4 | $1.81M | Sell |
14,600
-47,700
| -77% | -$7.08M | 0.01% | 1146 |
|
|
2018
Q3 | $10.5M | Buy |
62,300
+37,300
| +149% | +$6.41M | 0.06% | 313 |
|
|
2018
Q2 | $4.31M | Buy |
25,000
+12,200
| +95% | +$1.99M | 0.02% | 710 |
|
|
2018
Q1 | $1.93M | Buy |
12,800
+10,400
| +433% | +$1.53M | 0.01% | 1233 |
|
|
2017
Q4 | $321 | Sell |
2,400
-400
| -14% | -$55.5K | ﹤0.01% | 3023 |
|
|
2017
Q3 | $412 | Buy |
2,800
+400
| +17% | +$60.5K | ﹤0.01% | 2652 |
|
|
2017
Q2 | $375 | Sell |
2,400
-4,300
| -64% | -$658K | ﹤0.01% | 2625 |
|
|
2017
Q1 | $974 | Sell |
6,700
-1,100
| -14% | -$143K | 0.01% | 1672 |
|
|
2016
Q4 | $853K | Sell |
7,800
-3,900
| -33% | -$434K | 0.01% | 1645 |
|
|
2016
Q3 | $1.42M | Buy |
11,700
+2,500
| +27% | +$337K | 0.01% | 1251 |
|
|
2016
Q2 | $1.3M | Sell |
9,200
-1,800
| -16% | -$265K | 0.01% | 1364 |
|
|
2016
Q1 | $1.43M | Buy |
11,000
+1,400
| +15% | +$174K | 0.01% | 1090 |
|
|
2015
Q4 | $1.35M | Buy |
9,600
+6,400
| +200% | +$887K | 0.01% | 1032 |
|
|
2015
Q3 | $424K | Buy |
3,200
+1,100
| +52% | +$189K | ﹤0.01% | 1678 |
|
|
2015
Q2 | $370K | Sell |
2,100
-5,900
| -74% | -$1.06M | ﹤0.01% | 1937 |
|
|
2015
Q1 | $1.38M | Buy |
+8,000
| New | +$1.37M | 0.01% | 822 |
|
Other funds holding JAZZ
VPM
VCM
EC
Walleye Trading's JAZZ Position: Q1 2026 in Review
Walleye Trading sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 3,591 shares — an estimated $628K sold.
Walleye Trading first reported a position in JAZZ in Q2 2015 and held it in 23 quarters. The position peaked at $3.07M in Q2 2021. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Walleye Trading reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Walleye Trading sold 3,591 Jazz Pharmaceuticals shares in Q1 2026, an estimated $628K.
- Walleye Trading first reported a position in Jazz Pharmaceuticals in Q2 2015 and held it in 23 quarters.
- Walleye Trading's Jazz Pharmaceuticals position peaked at $3.07M in Q2 2021.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.